JAMP DIMETHYL FUMARATE CAPSULE (DELAYED RELEASE)

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

DIMETHYL FUMARATE

זמין מ:

JAMP PHARMA CORPORATION

קוד ATC:

L04AX07

INN (שם בינלאומי):

DIMETHYL FUMARATE

כמות:

240MG

טופס פרצבטיות:

CAPSULE (DELAYED RELEASE)

הרכב:

DIMETHYL FUMARATE 240MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

15G/50G

סוג מרשם:

Prescription

איזור תרפויטי:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0154210002; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2021-10-04

מאפייני מוצר

Pr
JAMP DIMETHYL FUMARATE
_ _
_(dimethyl fumarate delayed-release capsules)_ Page 1 of 43
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
JAMP DIMETHYL FUMARATE
Dimethyl fumarate delayed-release capsules
Delayed-release capsules, 120 mg and 240 mg, oral
Antineoplastic and Immunomodulating Agents
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
October 04, 2021
Date of Revision:
January 9, 2024
Submission Control Number: 277583
Pr
JAMP DIMETHYL FUMARATE
_ _
_(dimethyl fumarate delayed-release capsules)_ Page 2 of 43
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
01/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..............................................................................................................
4
1.2
Geriatrics
..............................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
..........................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
..................................................... 5
4.4
Administration
......................................................................